Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)
N/A
N/A
N/A
N/A
N/A
Not Enrolling
Both
Peritoneal Mesotheliomas
Both
Peritoneal Mesotheliomas
Trial Information
Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)
Observation of primary outcome:
- Overall Survival
- Disease-free survival
Influencing factors that will be observe:
- Sex
- Blood loss
- Time of surgery
- Number of resection and anastomosis
- Peritoneal Index (PI score)
- Cytoreductibility (CCR score)
Inclusion Criteria:
- Peritoneal mesothelioma
Exclusion Criteria:
- Non resectable disease
Type of Study:
Observational
Study Design:
Observational Model: Case-Crossover, Time Perspective: Retrospective
Outcome Measure:
Overall survival
Outcome Time Frame:
5 years
Safety Issue:
No
Principal Investigator
Lucas Sideris, MD
Investigator Role:
Study Director
Investigator Affiliation:
Maisonneuve-Rosemont Hospital
Authority:
Canada: Ethics Review Committee
Study ID:
Maisonneuve Rosemont Hospital
NCT ID:
NCT01812148
Start Date:
January 2012
Completion Date:
March 2013
Related Keywords:
- Peritoneal Mesotheliomas
- Peritoneal Mesotheliomas
- hyperthermic intra-peritoneal chemotherapy (HIPEC)
- Oxaliplatin
- Cytoreductive surgery
- Oxaliplatin HIPEC
- Fever
- Mesothelioma
Name | Location |
|---|
